Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease.

Background: Etiological treatment of Chagas disease in chronic asymptomatic patients is still in debate and the adverse effects of traditional drugs are one of the main concerns in clinical practice. This study evaluated retrospectively the safety profile of benznidazole (BZN) and identified predictive factors for definite treatment interruption and development of severe reactions in adult patients treated with BZN in Colombia.

Methods: Retrospective follow-up study conducted by review of medical records of adults with chronic Chagas disease treated with BZN in Colombia.